Lara Sullivan - 11 Sep 2023 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Issuer symbol
PYXS
Transactions as of
11 Sep 2023
Net transactions value
-$456,801
Form type
4
Filing time
13 Sep 2023, 20:16:19 UTC
Previous filing
08 Sep 2023
Next filing
18 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Sale $45,414 -20,000 -0.76% $2.27 2,605,182 11 Sep 2023 Direct F1, F2
transaction PYXS Common Stock Sale $11,071 -4,917 -0.19% $2.25 2,600,265 12 Sep 2023 Direct F1, F3
transaction PYXS Common Stock Sale $6,816 -3,000 -0.12% $2.27 2,597,265 13 Sep 2023 Direct F1, F4
transaction PYXS Common Stock Tax liability $393,500 -184,742 -7.1% $2.13 2,412,523 13 Sep 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4.
F2 The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36.
F3 The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30.
F4 The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34.
F5 Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units.